What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Two Phases of Protein Degradation: Ubiquitin-Proteasome and Autophagy

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Protein Degradation and Its Two Phases

Protein degradation is the controlled, enzymatic breakdown of proteins into amino acids and small peptides. It is not a passive decay process; it is a highly regulated, energy-dependent system that maintains protein homeostasis, removes damaged or toxic proteins, and allows rapid adaptation to changing cellular conditions. Every protein in a cell has a finite lifespan, and its destruction is as carefully choreographed as its synthesis on the Ribosome Make Protein machinery.

Why Protein Degradation Matters

Cells continuously synthesize proteins, but they must also degrade them for three fundamental reasons. First, quality control: misfolded, oxidized, or otherwise damaged proteins must be removed before they aggregate and become cytotoxic. Second, regulation: many regulatory proteins, such as cyclins, transcription factors, and signaling kinases, are short-lived by design. Their rapid degradation allows the cell to switch pathways on and off quickly. Third, adaptation: during starvation or developmental transitions, cells degrade existing proteins to recycle amino acids for new protein synthesis or energy production.

The half-life of a protein can range from minutes (e.g., ornithine decarboxylase, ~10 minutes) to days (e.g., hemoglobin, ~120 days). This enormous range is achieved not by a single degradation system, but by two distinct, complementary phases.

Overview of the Two Pathways

The two phases of protein degradation are the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway. The UPS is a highly selective, ATP-dependent process that degrades mostly short-lived, soluble proteins one at a time. It involves tagging a protein with a polyubiquitin chain and feeding it into a barrel-shaped protease complex called the proteasome.

The autophagy-lysosome pathway is a bulk degradation system that engulfs large portions of cytoplasm, long-lived proteins, protein aggregates, and entire organelles, delivering them to the lysosome for breakdown. Autophagy is induced by starvation and stress and is generally less selective than the UPS, though selective forms exist.

These two systems are not redundant. They handle different substrates, operate at different scales, and are regulated by different signals. Understanding both is essential for grasping how cells maintain proteostasis. For a broader overview of the degradation landscape, see Forms of Protein Degradation.

Phase 1: The Ubiquitin-Proteasome System (UPS)

The UPS is the primary pathway for the degradation of short-lived, soluble, and regulatory proteins. It accounts for approximately 80–90% of all intracellular protein degradation in a typical mammalian cell. The system has two major steps: covalent attachment of ubiquitin to the substrate, and subsequent recognition and degradation by the 26S proteasome.

Ubiquitin Activation and Conjugation

Ubiquitin is a 76-amino-acid protein (8.6 kDa) that is covalently attached to lysine residues on target proteins. The conjugation process requires three enzymes, acting in sequence:

E1 (ubiquitin-activating enzyme): In an ATP-dependent reaction, ubiquitin is adenylated and then linked via a thioester bond to a cysteine residue on the E1. Humans have two major E1 enzymes, UBA1 and UBA6.
E2 (ubiquitin-conjugating enzyme): The activated ubiquitin is transferred from the E1 to a cysteine on an E2 enzyme via a transthioesterification reaction. There are ~40 E2 enzymes in humans.
E3 (ubiquitin ligase): The E3 enzyme binds both the E2–ubiquitin complex and the substrate, catalyzing the formation of an isopeptide bond between the C-terminal glycine of ubiquitin (Gly76) and the ε-amino group of a lysine residue on the substrate. Humans have over 600 E3 ligases, which confer substrate specificity.

The E3 ligases are divided into three main families: RING (Really Interesting New Gene) finger ligases, which bring E2 and substrate together and are the most abundant; HECT (Homologous to E6-AP C-Terminus) ligases, which form a covalent intermediate with ubiquitin before transferring it to the substrate; and RBR (RING-Between-RING) ligases, which use a hybrid mechanism.

The first ubiquitin attached to a substrate is often followed by additional ubiquitin molecules, forming a polyubiquitin chain. Ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, K48, K63) and an N-terminal methionine (M1), each capable of forming a distinct chain linkage. The topology of the chain determines the fate of the substrate.

The 26S Proteasome

The 26S proteasome is a large, multi-subunit protease complex (~2.5 MDa) composed of two subcomplexes: the 20S core particle (CP) and the 19S regulatory particle (RP).

The 20S core particle is a barrel-shaped structure of four stacked heptameric rings: two outer α-rings and two inner β-rings. The α-subunits form a gated pore that restricts entry. The β-subunits contain the catalytic sites: β1 (caspase-like, cleaving after acidic residues), β2 (trypsin-like, cleaving after basic residues), and β5 (chymotrypsin-like, cleaving after hydrophobic residues). These active sites face the interior of the barrel, ensuring that proteolysis occurs in a sequestered chamber.

The 19S regulatory particle caps one or both ends of the 20S core. It consists of a base (containing six AAA+ ATPases: Rpt1–Rpt6) and a lid (containing ubiquitin receptors such as Rpn10 and Rpn13). The ATPases unfold the substrate and translocate it through the narrow pore into the 20S chamber. The lid contains a deubiquitinase, Rpn11, which removes ubiquitin chains as the substrate is threaded in.

Degradation by the 26S proteasome follows these steps:

Recognition: The 19S particle binds a polyubiquitinated substrate via ubiquitin receptors.
Deubiquitination: Rpn11 cleaves the ubiquitin chain, releasing free ubiquitin for reuse.
Unfolding and Translocation: The ATPase ring uses ATP hydrolysis to unfold the substrate and thread it through the central pore.
Proteolysis: The 20S core degrades the unfolded protein into peptides of 3–22 amino acids.
Release: Peptides are released into the cytosol, where they are further trimmed by aminopeptidases to amino acids.

The entire process consumes ATP at multiple steps: ubiquitin activation (2 ATP per ubiquitin), substrate unfolding, and translocation.

Substrate Recognition and Deubiquitination

The canonical degradation signal is a polyubiquitin chain linked through K48 of ubiquitin. A K48-linked chain of at least four ubiquitin moieties is the minimal signal for efficient proteasomal targeting. However, K11-linked chains also target substrates for degradation, particularly during the cell cycle, where the anaphase-promoting complex/cyclosome (APC/C) generates K11 linkages on cyclins.

Substrate recognition is not solely dependent on ubiquitin. Many substrates carry a degron—a short sequence motif that is recognized by an E3 ligase. Degrons can be constitutive (e.g., the N-end rule, where the N-terminal amino acid determines stability) or conditional (e.g., phosphorylation-dependent degrons, such as the phosphodegron in β-catenin recognized by the SCFβ-TrCP ligase after phosphorylation by GSK3β).

Deubiquitinating enzymes (DUBs), of which there are ~100 in humans, reverse ubiquitination. They serve two roles: they recycle ubiquitin from substrates before degradation, and they rescue proteins from degradation by removing ubiquitin chains. The balance between E3 ligases and DUBs determines the half-life of a substrate. For a deeper dive into the proteasome itself, see Proteasome Protein Degradation.

Phase 2: Autophagy-Lysosome Pathway

The autophagy-lysosome pathway is the second phase of protein degradation. It is responsible for degrading long-lived proteins, protein aggregates, damaged organelles, and even intracellular pathogens. Unlike the UPS, which degrades individual proteins, autophagy degrades cargo in bulk, often in membrane-bound compartments.

Macroautophagy: Sequestration and Delivery

Macroautophagy (hereafter "autophagy") is the most studied form. It involves the de novo formation of a double-membrane vesicle called an autophagosome, which engulfs a portion of cytoplasm and fuses with a lysosome to form an autolysosome, where the contents are degraded.

The process proceeds through distinct stages:

Initiation: Under nutrient-rich conditions, the kinase mTORC1 (mechanistic target of rapamycin complex 1) phosphorylates and inhibits the ULK1 complex (ULK1–ATG13–FIP200–ATG101). Upon starvation, mTORC1 dissociates, and ULK1 becomes active, phosphorylating downstream targets.
Nucleation: The ULK1 complex activates the class III PI3K complex (VPS34–Beclin-1–ATG14L), which produces phosphatidylinositol-3-phosphate (PI3P) at the phagophore assembly site (PAS). PI3P recruits effectors such as WIPI2.
Elongation: Two ubiquitin-like conjugation systems drive membrane expansion. In the ATG12 system, ATG12 is conjugated to ATG5 by ATG7 (E1-like) and ATG10 (E2-like), forming the ATG12–ATG5–ATG16L1 complex. In the LC3 system, the protein LC3 (microtubule-associated protein 1 light chain 3) is cleaved by ATG4 to form LC3-I, then conjugated to phosphatidylethanolamine (PE) by ATG7 and ATG3 to form LC3-II, which is anchored to the autophagosome membrane.
Cargo sequestration and closure: The autophagosome membrane expands around the cargo and seals. Selective autophagy receptors such as p62/SQSTM1 and NBR1 bind ubiquitinated cargo and link it to LC3 on the autophagosome membrane.
Fusion and degradation: The autophagosome fuses with a lysosome, a process mediated by SNARE proteins (STX17, SNAP29, VAMP8) and the small GTPase RAB7. The acidic lysosomal hydrolases then degrade the inner membrane and cargo.

The entire process from initiation to degradation takes approximately 10–20 minutes in cultured cells.

Chaperone-Mediated Autophagy

Chaperone-mediated autophagy (CMA) is a selective form of autophagy that does not involve vesicle formation. Instead, substrate proteins containing the pentapeptide motif KFERQ are recognized by the cytosolic chaperone Hsc70 (heat shock cognate 70). The chaperone-substrate complex is delivered to the lysosomal membrane, where it binds to the receptor protein LAMP-2A (lysosome-associated membrane protein type 2A). LAMP-2A multimerizes to form a translocation complex, and the substrate is unfolded and translocated across the lysosomal membrane with the help of a luminal form of Hsc70 (lys-Hsc70).

CMA degrades soluble, long-lived proteins and is particularly active during prolonged starvation. It is also involved in the degradation of specific regulatory proteins, such as the transcription factor HIF1α and the glycolytic enzyme GAPDH. CMA declines with age, contributing to the accumulation of damaged proteins in aging cells. For more on the chaperones involved, see Chaperone Protein.

Lysosomal Hydrolases

The lysosome is the terminal compartment of the autophagy pathway. It maintains an acidic lumen (pH 4.5–5.0) via the vacuolar H⁺-ATPase, which pumps protons into the lumen. This acidic environment is optimal for the ~60 soluble acid hydrolases, including:

Cathepsins (B, D, L, etc.): cysteine and aspartyl proteases that degrade proteins.
Lipases: degrade lipids.
Nucleases: degrade nucleic acids.
Glycosidases: degrade carbohydrates.

The lysosomal membrane is protected from self-digestion by a thick glycocalyx of heavily glycosylated proteins (e.g., LAMP-1, LAMP-2). After degradation, amino acids, free fatty acids, and sugars are exported to the cytosol via specific transporters (e.g., SLC38A9 for amino acids) and reused for biosynthesis or energy production.

Selectivity and Regulation of the Two Phases

Both degradation systems are selective, but they achieve selectivity through different mechanisms. The UPS uses the ubiquitin code and E3 ligases; autophagy uses autophagy receptors and, in the case of CMA, the KFERQ motif.

Ubiquitin Code

The ubiquitin code refers to the diverse topologies of ubiquitin chains and their distinct biological outcomes. K48-linked chains are the canonical proteasomal degradation signal. K11-linked chains also target substrates for degradation, especially in cell cycle regulation. K63-linked chains, by contrast, are primarily involved in signaling (e.g., NF-κB activation, DNA repair) and selective autophagy, not proteasomal degradation. M1-linked linear chains are involved in inflammatory signaling.

The code is "read" by ubiquitin-binding domains (UBDs) in downstream effectors. For example, the proteasomal subunit Rpn10 contains a UIM (ubiquitin-interacting motif) that binds K48 chains, while the autophagy receptor p62 contains a UBA domain that binds K63 chains and monoubiquitin.

Chaperone-Mediated Targeting

In addition to ubiquitin, chaperones play a role in substrate selection. In the UPS, molecular chaperones such as Hsp70 and Hsp90 can deliver misfolded proteins to E3 ligases like CHIP (C-terminus of Hsp70-interacting protein), which ubiquitinates them for proteasomal degradation. This is a critical branch of the protein quality control network, preventing the accumulation of Protein Misfolding products.

In CMA, Hsc70 recognizes the KFERQ motif directly. In macroautophagy, chaperones such as Hsp70 and Hsp90 can also deliver specific substrates to the autophagic machinery, a process called chaperone-assisted selective autophagy (CASA).

Nutrient and Stress Signaling

The master regulator of autophagy is mTORC1, a kinase complex that senses amino acids, growth factors, and energy status. Under nutrient-rich conditions, mTORC1 is active and phosphorylates ULK1 and ATG13, inhibiting autophagy. Under starvation, mTORC1 is inactivated, and autophagy is induced.

AMPK (AMP-activated protein kinase) is the cellular energy sensor. When ATP levels fall and AMP rises, AMPK is activated and phosphorylates ULK1 at different sites than mTORC1, promoting autophagy. AMPK also phosphorylates and activates the pro-autophagic kinase ULK1 directly.

The UPS is also regulated by signaling. For example, the SCF (Skp1-Cullin-F-box) family of E3 ligases is regulated by neddylation (conjugation of the ubiquitin-like protein NEDD8 to cullin), which is required for their activity. The proteasome itself can be upregulated by the transcription factor Nrf2 in response to oxidative stress.

Experimental Methods to Study Protein Degradation

Studying protein degradation requires methods to measure protein half-life, identify degradation signals, and distinguish between the UPS and autophagy.

Inhibitor-Based Approaches

The most common approach is to block a degradation pathway and observe the accumulation of substrates.

Proteasome inhibitors: MG132 is a peptide aldehyde that reversibly inhibits the chymotrypsin-like activity of the 20S proteasome. It is used at concentrations of 10–50 µM in cell culture. Bortezomib (Velcade) is a boronic acid derivative that is more potent and is used clinically. Epoxomicin is an irreversible, highly specific proteasome inhibitor.
Autophagy inhibitors: Chloroquine and hydroxychloroquine raise lysosomal pH, blocking lysosomal degradation. Bafilomycin A1 is a specific inhibitor of the vacuolar H⁺-ATPase and is used at 50–200 nM. 3-Methyladenine (3-MA) inhibits class III PI3K and blocks autophagy initiation, though it has off-target effects.
Lysosomal protease inhibitors: Leupeptin (inhibits cathepsins B and L) and pepstatin A (inhibits cathepsin D) are often used in combination to block lysosomal proteolysis.

A key caveat: MG132 also inhibits calpains and cathepsins at high concentrations, and chloroquine can affect other acidic compartments. Always validate with genetic approaches (e.g., siRNA knockdown of ATG5 or PSMB5).

Fluorescent Reporters (GFP-based)

Reporter proteins allow real-time monitoring of degradation.

GFP-LC3: When autophagy is induced, LC3-II is conjugated to autophagosome membranes. GFP-LC3 forms puncta (dots) that can be counted by fluorescence microscopy. However, GFP-LC3 puncta can also form in non-autophagic contexts, so it should be combined with lysosomal inhibitors to measure autophagic flux.
GFP-p62: p62 is degraded by autophagy; its levels inversely correlate with autophagic activity. A decrease in p62 indicates autophagy induction.
Degron reporters: A short degron (e.g., the CL1 degron) fused to GFP creates an unstable protein that is degraded by the UPS. Inhibition of the proteasome leads to GFP accumulation, which can be measured by flow cytometry or fluorescence.
tandem fluorescent reporters: The mCherry-GFP-LC3 reporter exploits the differential pH sensitivity of GFP (quenched in acidic compartments) and mCherry (stable). In autophagosomes (neutral pH), both fluoresce; in autolysosomes (acidic pH), only mCherry fluoresces. The ratio of red-only to yellow puncta measures autophagic flux.

Mass Spectrometry for Ubiquitin Remodeling

Mass spectrometry can identify ubiquitination sites and chain topologies on a proteome-wide scale. After digestion with trypsin, ubiquitinated peptides retain a di-glycine (GG) remnant on the modified lysine. Antibodies against the GG remnant (e.g., the K-ε-GG antibody from Cell Signaling Technology) are used to enrich for ubiquitinated peptides, which are then identified by LC-MS/MS. This approach, called ubiquitin remnant profiling, can quantify changes in ubiquitination under different conditions.

To study degradation kinetics, the cycloheximide chase assay is standard. Cells are treated with cycloheximide (typically 50–100 µg/mL) to block new protein synthesis, and the levels of the protein of interest are measured by immunoblotting at successive time points (e.g., 0, 1, 2, 4, 8 hours). The half-life is calculated from the decay curve. A pulse-chase experiment uses radioactive (³⁵S-methionine) or non-radioactive (e.g., SILAC) labeling to track a protein's fate over time.

Physiological Roles and Disease Implications

Defects in either phase of protein degradation are central to numerous diseases.

UPS in Cancer and Neurodegeneration

The UPS regulates the levels of many oncoproteins and tumor suppressors. The tumor suppressor p53 is degraded by the E3 ligase MDM2; overexpression of MDM2 in cancers leads to p53 loss and uncontrolled proliferation. Conversely, the oncoprotein c-Myc is degraded by the SCF-Fbw7 ligase; loss of Fbw7 stabilizes c-Myc and promotes tumorigenesis.

The proteasome inhibitor bortezomib is used to treat multiple myeloma and mantle cell lymphoma. It works by overwhelming the already stressed proteostasis network of cancer cells, leading to accumulation of misfolded proteins and apoptosis.

In neurodegeneration, the accumulation of ubiquitinated protein aggregates is a hallmark of Parkinson's disease (Lewy bodies containing α-synuclein), Alzheimer's disease (neurofibrillary tangles of tau), and Huntington's disease (polyglutamine aggregates of huntingtin). Mutations in the E3 ligase parkin cause an autosomal recessive form of Parkinson's disease, highlighting the importance of the UPS in neuronal survival.

Autophagy in Metabolic and Neurodegenerative Diseases

Autophagy is a key regulator of metabolism. In the liver, autophagy degrades lipid droplets (lipophagy) and glycogen (glycophagy). Defective autophagy in hepatocytes leads to steatosis and insulin resistance. In pancreatic β-cells, autophagy maintains mitochondrial quality; its failure contributes to type 2 diabetes.

In neurons, autophagy is essential for clearing protein aggregates and damaged mitochondria. Mice with conditional knockout of ATG5 or ATG7 in neurons develop progressive motor deficits and accumulate ubiquitin-positive inclusions, recapitulating features of neurodegeneration. Mutations in the autophagy receptor p62 are associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Therapeutic strategies include rapamycin (an mTORC1 inhibitor) to induce autophagy in neurodegenerative diseases, and hydroxychloroquine (an autophagy inhibitor) in cancer, where autophagy can promote tumor survival under stress. The field of Targeted Protein Degradation is also developing small molecules such as PROTACs (proteolysis-targeting chimeras) that hijack the UPS to degrade disease-causing proteins.

Common Pitfalls and Misconceptions

Students frequently misunderstand several aspects of protein degradation. Here are the most common errors.

Ubiquitin Is Not Only for Degradation

Ubiquitination is a versatile post-translational modification. K48-linked polyubiquitination signals for proteasomal degradation, but monoubiquitination and K63-linked chains regulate DNA repair, endocytosis, and NF-κB signaling. Not every ubiquitinated protein is destined for destruction. Always consider the chain topology and the context. For a broader view of modifications, see Post Translational Protein Modification.

Autophagy vs. Apoptosis

Autophagy is a survival mechanism; apoptosis is programmed cell death. Autophagy degrades cellular components to recycle nutrients and remove damage, keeping the cell alive. Apoptosis is an active, caspase-dependent process that dismantles the cell. They are often connected—autophagy can delay apoptosis, and excessive autophagy can lead to autophagic cell death—but they are distinct pathways. Do not describe autophagy as "cell suicide."

Half-Life and Degradation Rate

Half-life is the time required for half of the protein pool to be degraded. It is not the same as the degradation rate constant (k), though they are related: t½ = ln(2)/k. A short half-life means rapid degradation, not necessarily low abundance. Many abundant proteins (e.g., actin) are long-lived, while many scarce regulatory proteins (e.g., cyclins) are short-lived.

UPS Degrades Only Misfolded Proteins

This is incorrect. The UPS degrades many properly folded, functional proteins that are short-lived by design. Cyclins, transcription factors, and signaling enzymes are all degraded by the UPS while fully folded. Misfolded proteins are also degraded, but they are only one class of substrates.

Autophagy Is Only for Starvation

While autophagy is strongly induced by starvation, it operates at a basal level in all cells at all times. Basal autophagy is essential for quality control of organelles and long-lived proteins. Even in nutrient-rich conditions, autophagy continuously removes damaged mitochondria (mitophagy) and protein aggregates.

Proteasome and Lysosome Are the Same

They are different organelles with different proteases. The proteasome is a cytosolic complex that degrades ubiquitinated proteins into peptides. The lysosome is a membrane-bound organelle with an acidic lumen that degrades proteins, lipids, nucleic acids, and carbohydrates. They do not fuse with each other; they are independent systems.

Summary and Key Takeaways

The two phases of protein degradation—the ubiquitin-proteasome system and the autophagy-lysosome pathway—are complementary systems that maintain cellular proteostasis. The UPS is selective, ATP-dependent, and degrades short-lived, soluble proteins via ubiquitin tagging and proteasomal proteolysis. Autophagy is a bulk degradation system that engulfs cytoplasm, organelles, and aggregates and delivers them to lysosomes for breakdown.

Both systems are tightly regulated by nutrient and stress signals, and both are essential for health. Defects in either pathway contribute to cancer, neurodegeneration, and metabolic disease. Understanding the mechanisms, regulation, and experimental approaches to study these pathways is fundamental to molecular biology.

Frequently Asked Questions

What are the two phases of protein degradation?

The two phases are the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway. The UPS degrades short-lived, soluble proteins via ubiquitin tagging and proteasomal proteolysis. The autophagy-lysosome pathway degrades long-lived proteins, aggregates, and organelles by engulfing them in autophagosomes and delivering them to lysosomes.

How do the two phases of protein degradation differ?

The UPS is highly selective, degrades one protein at a time, requires ATP, and produces short peptides. Autophagy is bulkier, can degrade entire organelles, is induced by starvation, and produces amino acids and other metabolites. The UPS uses ubiquitin as a degradation signal; autophagy can use ubiquitin (for selective autophagy) but also engulfs unmodified cytoplasm.

What is the role of ubiquitin in protein degradation?

Ubiquitin is a small protein that is covalently attached to lysine residues on substrates via a cascade of E1, E2, and E3 enzymes. A polyubiquitin chain linked through K48 of ubiquitin is the canonical signal for proteasomal degradation. Ubiquitin also serves non-degradative roles in signaling and trafficking.

What are common inhibitors used to study protein degradation?

Proteasome inhibitors: MG132, bortezomib, epoxomicin. Autophagy inhibitors: chloroquine, bafilomycin A1, 3-methyladenine. Lysosomal protease inhibitors: leupeptin, pepstatin A. These are used to block degradation and measure substrate accumulation or flux.

Can a protein be degraded by both phases?

Yes. Some proteins can be degraded by either pathway depending on the context. For example, p62 is degraded by autophagy, but it can also be ubiquitinated and degraded by the proteasome under certain conditions. The choice depends on the ubiquitin chain topology, the presence of autophagy receptors, and the cellular stress state.

Why is protein degradation important for the cell?

Protein degradation is essential for quality control (removing misfolded proteins), regulation (controlling levels of short-lived regulatory proteins), and adaptation (recycling amino acids during starvation). Without degradation, cells accumulate toxic aggregates and cannot respond to changing conditions.

What happens if protein degradation fails?

Failure of protein degradation leads to the accumulation of damaged proteins and organelles, which can trigger cellular stress, inflammation, and cell death. In humans, this manifests as neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's), cancer, and metabolic disorders. Proteasome inhibitors are used in cancer therapy precisely because they overwhelm the degradation capacity of tumor cells.

Key Takeaways

The two phases of protein degradation are the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway; they are complementary, not redundant.
The UPS degrades short-lived, soluble proteins via K48-linked polyubiquitination and the 26S proteasome, consuming ATP at multiple steps.
Autophagy degrades long-lived proteins, aggregates, and organelles via autophagosome formation and lysosomal hydrolases; it is induced by starvation and regulated by mTORC1 and AMPK.
Selectivity in the UPS is achieved by E3 ligases and ubiquitin chain topology; in autophagy, by receptors like p62 and the KFERQ motif in chaperone-mediated autophagy.
Experimental tools include proteasome inhibitors (MG132), autophagy inhibitors (chloroquine), GFP-LC3 reporters, and cycloheximide chase assays.
Defects in either pathway cause cancer, neurodegeneration, and metabolic disease; both are therapeutic targets.
Ubiquitin is not only a degradation signal; it also regulates signaling, DNA repair, and endocytosis depending on chain linkage.